Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureSarah S. Nasr, Owen E. Tabah, Stephanie Poore, Gregg A. Duncan
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
The dawn of mRNA vaccines: the COVID-19 case
10.1016/j.jconrel.2021.03.043 · 2021
Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing
10.1038/s41565-020-0669-6 · 2020
On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles
10.1073/pnas.2109256118 · 2021
Spleen SORT LNP generated in situ CAR T cells extend survival in a mouse model of lymphoreplete B cell lymphoma
10.1002/anie.202310395 · 2023
Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs
10.1038/s41578-022-00529-7 · 2023
Tissue-specific gene delivery approaches
10.1002/btm2.70125 · 2026
The interplay of quaternary ammonium lipid structure and protein corona on lung-specific mRNA delivery by selective organ targeting (SORT) nanoparticles
10.1016/j.jconrel.2023.07.058 · 2023
IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines
10.1038/s41590-022-01160-y · 2022
The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
10.4049/jimmunol.206.supp.30.01 · 2021
Pro-inflammatory concerns with lipid nanoparticles
10.1016/j.ymthe.2022.04.011 · 2022
Sulfonium lipid nanoparticles for intranasal mRNA delivery to lung epithelial and immune cells
10.1016/j.actbio.2025.08.032 · 2025
‘Tripod-like’ lung-targeting (LuT) lipids for highly efficient and selective LNPs for gene delivery and editing
10.1038/s41551-026-01615-9 · 2026
Airway epithelial cell-specific delivery of lipid nanoparticles loading siRNA for asthma treatment
10.1016/j.jconrel.2022.10.020 · 2022
Impact of formulation and process parameters on the stability and bioactivity of RNA-loaded lipid nanoparticles during nebulization
10.1016/j.ejps.2025.107383 · 2026
Engineering lipid nanoparticles for enhanced intracellular delivery of mRNA through inhalation
10.1021/acsnano.2c05647 · 2022
Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs
10.1038/s41551-021-00786-x · 2021
Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy
10.1038/s41467-024-51056-8 · 2024
Optimization of ionizable lipids for aerosolizable mRNA lipid nanoparticles
10.1002/btm2.10580 · 2023
Increase nebulization stability of lipid nanoparticles by integrating a DNA supramolecular hydrogel
10.1021/acsmacrolett.3c00183 · 2023
Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination
10.1038/s41467-024-53914-x · 2024
Inhalable mRNA therapeutics for pulmonary diseases: challenges in delivery and advances in carrier design
10.26599/nr.2025.94907874 · 2025
RNA lipid nanoparticles stabilized during nebulization through excipient selection
10.1039/d4na01034e · 2025
Discovery of peptides for ligand-mediated delivery of mRNA lipid nanoparticles to cystic fibrosis lung epithelia
10.1016/j.omtn.2024.102375 · 2024
PEGylation-dependent cell uptake of lipid nanoparticles revealed by spatiotemporal correlation spectroscopy
10.1021/acsptsci.4c00419 · 2024
PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles
10.1078/0171-9335-00363 · 2004
Questioning the use of PEGylation for drug delivery
10.1007/s13346-013-0176-5 · 2013
Physicochemical properties of nanoparticles affecting their fate and the physiological function of pulmonary surfactants
10.1016/j.actbio.2021.11.034 · 2022
The influence of a biomimetic pulmonary surfactant modification on the in vivo fate of nanoparticles in the lung
10.1016/j.actbio.2022.05.038 · 2022
Development and characterization of lung surfactant-coated polymer nanoparticles for pulmonary drug delivery
10.1016/j.bioadv.2023.213430 · 2023
Inhalable gene therapy and the lung surfactant problem
10.1021/acs.nanolett.3c03547 · 2023
The interplay of lung surfactant proteins and lipids assimilates the macrophage clearance of nanoparticles. Prow TW, editor
10.1371/journal.pone.0040775 · 2012
Elucidating inhaled liposome surface charge on its interaction with biological barriers in the lung
10.1016/j.ejpb.2022.01.009 · 2022
Pulmonary surfactant inhibition of nanoparticle uptake by alveolar epithelial cells
10.1038/s41598-020-76332-7 · 2020
Barrier or carrier? Pulmonary surfactant and drug delivery
10.1016/j.ejpb.2015.02.014 · 2015
Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future
10.1038/pr.2016.203 · 2017
In vitro characterization and in vivo comparison of the pulmonary outcomes of Poractant alfa and Calsurf in ventilated preterm rabbits. Simeoni U, editor
10.1371/journal.pone.0230229 · 2020
Lung surfactant phospholipids in different animal species
10.1007/bf02534515 · 1984
Surfactant protein B (SP-B) enhances the cellular siRNA delivery of proteolipid coated nanogels for inhalation therapy
10.1016/j.actbio.2018.08.012 · 2018
Surfactant protein B promotes cytosolic SiRNA delivery by adopting a virus-like mechanism of action
10.1021/acsnano.0c04489 · 2021
Pulmonary surfactant protein SP-C regulates lipid vesicle uptake by alveolar type II cells and macrophages: role of lipids, palmitoylation, and environment
2025
Exploring the intrinsic micro−/nanoparticle size on their in vivo fate after lung delivery
10.1016/j.jconrel.2022.05.006 · doi-reference
Update on macrophage clearance of inhaled micro- and nanoparticles
10.1089/jamp.2009.0797 · doi-reference
Size-tunable strategies for a tumor targeted drug delivery system
10.1021/acscentsci.9b01139 · doi-reference
The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
10.1016/j.isci.2021.103479 · doi-reference
Hydrophobic pulmonary surfactant proteins SP-B and SP-C induce pore formation in planar lipid membranes: evidence for proteolipid pores
10.1016/j.bpj.2012.11.014 · doi-reference
Towards the molecular mechanism of pulmonary surfactant protein SP-B: at the crossroad of membrane permeability and interfacial lipid transfer
10.1016/j.jmb.2020.166749 · doi-reference
A combined action of pulmonary surfactant proteins SP-B and SP-C modulates permeability and dynamics of phospholipid membranes
10.1042/bj20110681 · doi-reference
A modified squeeze-out mechanism for generating high surface pressures with pulmonary surfactant
10.1016/j.bbamem.2011.12.007 · doi-reference
Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR–Cas gene editing
10.1038/s41563-020-00886-0 · doi-reference
Key design features of lipid nanoparticles and electrostatic charge-based lipid nanoparticle targeting
10.3390/pharmaceutics15041184 · doi-reference
Phosphatidylethanolamine and cholesterol promote hemifusion formation: a tug of war between membrane interfacial order and intrinsic negative curvature of lipids
10.1021/acs.jpcb.3c04489 · doi-reference
Spatial conformation of ionizable lipids regulates endosomal membrane disruption
10.1021/jacs.5c10908 · doi-reference
An anionic phospholipid enables the hydrophobic surfactant proteins to alter spontaneous curvature
10.1016/j.bpj.2012.12.041 · doi-reference
The importance of apparent pKa in the development of nanoparticles encapsulating siRNA and mRNA
10.1016/j.tips.2021.03.002 · doi-reference
Mechanism of pH-sensitive amphiphilic endosomal escape of ionizable lipid nanoparticles for cytosolic nucleic acid delivery
10.1007/s11095-025-03890-8 · doi-reference
An adeno-associated viral vector capable of penetrating the mucus barrier to inhaled gene therapy
10.1016/j.omtm.2018.03.006 · doi-reference
Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy
10.1073/pnas.1502281112 · doi-reference
Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung
10.1080/17425247.2021.1854222 · doi-reference
Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation
10.1126/sciadv.1601556 · doi-reference
Mucus models to evaluate the diffusion of drugs and particles
10.1016/j.addr.2017.11.001 · doi-reference
Mucin biopolymers and their barrier function at airway surfaces
10.1021/acs.langmuir.0c02410 · doi-reference
Microstructural alterations of sputum in cystic fibrosis lung disease
10.1172/jci.insight.88198 · doi-reference
Machine learning-informed predictions of nanoparticle mobility and fate in the mucus barrier
10.1063/5.0091025 · doi-reference
High-density branched PEGylation for nanoparticle drug delivery
10.1007/s12195-022-00727-x · doi-reference
Structure–function correlations of pulmonary surfactant protein SP-B and the saposin-like family of proteins
10.1007/s00249-012-0858-9 · doi-reference
Pulmonary surfactant protein B: a structural model and a functional analogue
10.1016/s0005-2736(00)00199-1 · doi-reference
Effects of lung surfactant proteins, SP-B and SP-C, and palmitic acid on monolayer stability
10.1016/s0006-3495(01)76198-x · doi-reference
Solubility versus electrostatics: what determines lipid/protein interaction in lung surfactant
10.1529/biophysj.107.106765 · doi-reference
Lung surfactant as a biophysical assay for inhalation toxicology
10.1016/j.crtox.2022.100101 · doi-reference
Emulation of the structure of the Saposin protein fold by a lung surfactant peptide construct of surfactant protein B
10.1371/journal.pone.0276787 · doi-reference
Interaction of pulmonary surfactant protein SP-A with DPPC/egg-PG bilayers
10.1016/s0006-3495(03)74663-3 · doi-reference
Pulmonary surfactant and drug delivery: focusing on the role of surfactant proteins
10.1016/j.jconrel.2018.10.012 · doi-reference
Pulmonary surfactant: a unique biomaterial with life-saving therapeutic applications
10.2174/0929867328666210825110421 · doi-reference
Surfactant protein B: disulfide bridges, structural properties and kringle similarities
10.1021/bi00242a015 · doi-reference
Surfactant-associated proteins: functions and structural variation
10.1016/s1095-6433(01)00308-7 · doi-reference
Role of pulmonary surfactant components in surface film formation and dynamics
10.1016/s0005-2736(00)00256-x · doi-reference
Particle tracking in drug and gene delivery research: state-of-the-art applications and methods
10.1016/j.addr.2015.03.017 · doi-reference